<DOC>
	<DOCNO>NCT01563913</DOCNO>
	<brief_summary>The purpose research study measure safety ( side effect ) Omega 3 Fatty acid call docosahexanoic acid ( DHA ) measure dyskinesia ( involuntary movement ) Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>Reducing Dyskinesia Parkinson 's Disease With Omega-3 Fatty Acids</brief_title>
	<detailed_description>Levodopa induce dyskinesia ( LID ) involuntary , abnormal movement occur patient Parkinson disease ( PD ) consequence chronic use effective symptomatic drug , levodopa ( LD ) . LID range subtle unobtrusive mark disable . There surprisingly treatment LID , include amantadine deep brain stimulation . In many instance , amantadine either poorly tolerate , provide inadequate benefit , small minority appropriate candidate surgery . Given find docosahexanoic acid ( abundant omega-3 fatty acid brain ) , delay onset reduces severity dyskinesia two different animal model LID , trial docosahexanoic acid ( DHA ) PD subject start LD part drug regimen , prevent slow progression LID warrant . Prior embark large trial , preliminary data safety tolerability DHA PD subject need , collection data primary outcome pilot project proposal . 40 subject yet use levodopa , begin randomize daily DHA placebo . Safety laboratory testing , adverse event monitoring , DHA plasma CSF level well compliance/subject retention outcomes collect . In addition , preliminary data modification incidence rate collect compare two treatment group . This information aid calculate appropriate sample size treatment period large definitive future study . Dyskinesia manifest overwhelmingly plasma levodopa level high enough cause anti-parkinsonian benefit , lessen stop levodopa level drop threshold . Thus , subject 's dyskinesia measurement must occur levodopa administration period . Dyskinesia measurement occur two-hour levodopa cycle administer subject week 0 , 6 , 24 , 52 , 76 . It expect good proportion subject manifest dyskinesia within two-year observation period , previous study use objective mean measure dyskinesia report incidence rate 67 % great within first year levodopa use . An instrument measure dyskinesia develop center use additional outcome , expect measure dyskinesia accurately great sensitivity gold standard method clinical rating scale . By conclusion pilot project , safety tolerability , subject retention compliance , plasma/CSF level DHA administration determine . Trends dyskinesia development may measure . This provide need background information proceed future large trial DHA prevent dyskinesia PD .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<criteria>Diagnosed Parkinsons disease No levodopa ( Sinemet ) treatment prior exposure levodopa Prior exposure levodopa Unable stand 1 minute without aid Sensory deficits foot Significant cognitive impairment Current use dopamine receptor block medication ( depakote , lithium , amiodarone , tetrabenazine , metoclopramide , dronabinol ) Current fish oil lutein supplementation Allergy soy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Parkinsons disease</keyword>
	<keyword>supplement</keyword>
	<keyword>DHA</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>abnormal movement</keyword>
</DOC>